Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features

Table 4 Autoantibodies in different disease subsets in 863 individual systemic sclerosis patients

	Limited (N= 513)		Diffuse (N= 173)		Overlap (N= 108)		Undifferentiated (N= 64)
Antibodies	n(%)	OR^a (P-value)	n(%)	OR (P-value)	n(%)	OR (P-value)	n(%)
ACA	253 (49.3)	5.00 ( P < 0.0001)	12 (6.9)		16 (14.8)		28 (43.8)
ATA	141 (27.5)		98 (56.6)	4.26 ( P < 0.0001)	11 (10.2)		9 (14.1)
Anti-RNAP	14 (2.7)		14 (8.1)	3.11 ( P = 0.0029)	2 (1.9)		2 (3.1)
Anti-U1-RNP	7 (1.4)		0 (0.0)		31 (28.7)	30.00 ( P < 0.0001)	2 (3.1)
Anti-PM-Scl	16 (3.1)		2 (1.2)		22 (20.4)	9.40 ( P < 0.0001)	2 (3.1)
Anti-fibrillarin	3 (0.6)		8 (4.6)	8.32 ( P = 0.0005)	1 (0.9)		0 (0.0)
Anti-To	1 (0.2)		0 (0)		1 (0.9)		0 (0.0)
Anti-Jo-1/Pl-7/OJ	0 (0.0)		0 (0)		4 (3.7)	65.07 ( P = 0.0002)	0 (0.0)
Anti-U11-RNP	0 (0.0)		1 (0.6)		0 (0.0)		0 (0.0)
Anti-Ku	5 (1.0)		1 (0.6)		3 (2.8)		1 (1.6)
Anti-SL	5 (1.0)		3 (1.7)		1 (0.9)		0 (0.0)
Anti-Sm	0 (0.0)		0 (0.0)		3 (2.8)	21.54 (P = 0.0069)	0 (0.0)
Anti-NOR-90	5 (1.0)		0 (0.0)		1 (0.9)		0 (0.0)
AMA	28 (5.5)		4 (2.3)		4 (3.7)		5 (7.8)
Anti-Sp100	3 (0.6)		0 (0.0)		0 (0.0)		1 (1.6)
Anti-Ro52	125 (24.4)	1.50 (P = 0.023)	20 (11.6)		27 (25.0)		15 (23.4)
Anti-Ro60	28 (5.4)		14 (8.1)		13 (12.0)	2.11 (P = 0.0382)	4 (6.3)
Anti-La	9 (1.8)		3 (1.7)		1 (0.9)		3 (4.7)
Anti-p25/p23	24 (4.5)	4.25 ( P = 0.0031)	0 (0.0)		2 (1.9)		2 (3.1)
Other	209 (40.7)		74 (42.8)		44 (40.7)		34 (53.1)
ANA-negative	32 (6.2)		6 (3.5)		5 (4.6)		7 (10.9)

ACA, anti-centromere antibodies; AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; ATA, anti-topoisomerase I antibodies; RNAP, RNA polymerase;. ^aOR for antibody in that subset compared with all other subsets. Only significant positive associations are documented by OR, and those with P-values < 0.005 are printed in bold.

ISSN: 1478-6362